The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Fstar Therapeutics; Gilead Sciences; Novocure
Stock and Other Ownership Interests - Fstar Therapeutics; Gilead Sciences; Novocure
Consulting or Advisory Role - Fstar Therapeutics
EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Shionogi; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Scott Peter Owen
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Roche Canada; Takeda
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Calithera Biosciences; D2G Oncology; Exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Natera; Regeneron; Sanofi/Regeneron; Surface Oncology; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
David Vicente
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca
 
Sabeen Fatima Mekan
Stock and Other Ownership Interests - Daiichi Sankyo
 
Farnoush Safavi
No Relationships to Disclose
 
Nelumka Fernando
No Relationships to Disclose
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - ACT Genomics-Sanomics Group; AstraZeneca; Aurora Tele-Oncology Platform; HUTCHMED; Lunit
Stock and Other Ownership Interests - ACT Genomics-Sanomics Group; Aurora Tele-Oncology Platform; HUTCHMED
Honoraria - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; Gilead Sciences; Gritstone Bio; Guardant Health; InMed; Lilly; Lucence; Medscape; Merck Sharp & Dohme; Novartis; Origimed; PeerVoice; Permanyer Publications; Pfizer; Physicans' Education Resource; Prime Oncology; Research to Practice; Roche; Sanofi Aventis GmbH; Shanghai BeBirds Translation & Consulting; Suzhou Liangyihui Network Technology; Taiho Pharmaceutical; Takeda; touchIME
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; Berry Oncology; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CStone Pharmaceuticals; Curio Science; D3; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; G1 Therapeutics; geneDecode; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Incyte; Inivata; IQvia; Janssen; Lilly; Loxo; Lunit; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; Puma Biotechnology; Qiming Development (HK) Ltd.; Roche; SFJ Pharmaceuticals Group; Takeda; Vertex; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)